The clinical spectrum of amiodarone-associated optic neuropathy

Journal of the National Medical Association

Volumn 96, Issue 11, 2004, Pages 1477-1491

  Johnson, Lenworth N ^a   Krohel, Gregory B ^b   Thomas, Eric R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

Amiodarone; Optic neuropathy; Retrobulbar; Vision loss; Visual field loss

Indexed keywords

AMIODARONE;

BLINDNESS; CLINICAL FEATURE; COLOR VISION DEFECT; DISEASE CLASSIFICATION; HUMAN; INTRACRANIAL PRESSURE; ISCHEMIC OPTIC NEUROPATHY; LUMBAR PUNCTURE; OPTIC NERVE DISEASE; PAPILLEDEMA; PRIORITY JOURNAL; RETROBULBAR OPTIC NEUROPATHY; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; OPTIC DISK; OPTIC NERVE DISEASES; TIME FACTORS;

EID: 8344269393     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Ghosh M, McCulloch C. Amiodarone-induced ultrastructural changes in human eyes. Can J Ophthalmol. 1984;19:178-186.
2. Chew E, Ghosh M, McCullouch C. Amiodarone-induced cornea verticillata. Can J Ophthalmol. 1982;17:96-99.
3. Gittinger Jr JW, Asdourian GK. Papillopathy caused by amiodarone. Arch Ophthalmol. 1987;105:349-351.
4. Feiner LA, Younge BR, Kazmier FJ, et al. Optic neuropathy and amiodarone therapy. Mayo Clin Proc. 1987;62:702-717.
5. Dewachter A, Lievens H. Amiodarone and optic neuropathy. Bull Soc Belge Ophthalmol. 1988;227:47-50.
6. Nazarian SM, Jay WM. Bilateral optic neuropathy associated with amiodarone therapy. J Clin Neuro-Ophthalmol. 1988;8:25-28.
7. Garrett SN, Kearney JJ, Schiffman JS. Amiodarone optic neuropathy. J Clin Neuro-Ophthalmol. 1988;8:105-110.
8. Ferriero JL, Isern Longares JA, Ramón Moya AF. Neuropatía óptica por omiodarona. Neurologia. 1990;5:160-163.
9. Sedwick LA, Hedges III TR, Newman NJ. Getting to the heart of visual loss: when cardiac medication may be dangerous to the optic nerves. Surv Ophthalmol. 1992;36:366-372.
10. Krieg P, Schipper I. Bilaterale Opticusneruopathie nach Amiodarone-Therapie. Klin Monatsbl Augenheilkd. 1992;200:128-132.
11. Belec L, Davila G, Bleibel JM, et al. Neuropathie optique bilatérale au cours d'un traitement prolongé par l'amiodarone. Ann Med Interne. 1992;143:349-350.
12. Seemongal-Dass RR, Spencer SR. Bilateral optic neuropathy linked with amiodarone (letter). Eye. 1998;12:474-484.
13. Palimar P, Cota N. Bilateral anterior ischemic optic neuropathy following amiodarone (letter). Eye. 1998;12:894-896.
14. Sreih AG, Schoenfeld MH, Marieb MA. Optic neuropathy following amiodarone therapy. Pace. 1999;22:1108-1110.
15. Bartolucci J, Ibáñez P, Verdugo C, et al. Neuritis retrobulbar inducida por amiodarona. Caso clínico. [Amiodarone-induced retrobulbar neuritis. Report of one case]. Rev Méd Chile. 1999;127:827-830.
16. Gobbele R, Dahlke C, Mull M, et al. Amiodaron-assoziierte bilaterale Optikusatrophie. Eine Kasuistik. Nervenarzt. 1999;70:560-565.
17. Speicher MA, Goldman MH, Chrousos GA. Amiodarone optic neuropathy without disc edema. J Neuro-Ophthalmol. 2000;20:171-172.
18. Eryilmaz T, Atilla H, Batioólu F, et al. Amiodarone-related optic neuropathy. Jpn J Ophthalmol. 2000;44:565-568.
19. Leifert D, Hansen LL, Gerling J. Amiodaron-Optikusneuropathie: ein eigenständiges Krankheitsbild? Klin Monatsbl Augenh. 2000;217:171-177.
20. Kristin N, Ulbig M, Akutes Papillenödem 69-jähriger Patient mit bilateralem akutem Papillenödem. Ophthalmologe. 2001;98:212-213.
21. Polak BCP, Tutein Nolthenius PA, Rietveld E. Slecht-ziendheid door opticusneuropathie bij 2 patienten die amiodaron respectievelijk ethambutol en isoniazide gebruikten. Nederlands Tijdschrift Geneeskunde. 2001;145:922-926.
22. Uebermuth C, Gerke E. Zunächst einseitige, später beidseitige Optikopathie Amiodaron als Ursache? Ophthalmologe. 2002;99:470-473.
23. Castells DD, Teitelbaum BA, Tresley DJ. Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy. Optometry. 2002;73:113-121.
24. Nagra PK, Foroozan R, Savino PJ, et al, Amiodarone-induced optic neuropathy. Br J Ophthalmol. 2003;87:420-422.
25. Fikkers BG, Bogousslavsky J, Regli F, et al. Pseudotumor cerebri with amiodarone. J Neurol Neurosurg Psychiatry. 1986;49:606.
26. Van Zandijcke M, DeWachter A. pseudotumor cerebri with amiodarone. J Neurol Neurosurg Psychiatry. 1986;49:1463-1464.
27. Grogan WA, Narkun DM. Pseudotumor cerebri with amiodarone. J Neurol Neurosurg Psychiatry. 1987;50:651.
28. Mindel JM. Amiodarone and optic neuropathy - a medicolegal issue. Surv Ophthalmol. 1998;42:358-359.
29. Scheier L. Bitter pill. When a drug firm breaks the rules, it has few natural enemies. Chicago Tribune. 2003(April 20): p. 8.
30. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol. 1999;127:610-612.
31. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the State of Missouri and Los Angeles County, CA. J Neuro-Ophthalmol. 1994;14:38-44.
32. Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123:103-107.
33. Johnson LN, Krohel GB, Allen SD, et al. Recurrent herpes labialis as a potential risk factor for nonarteritic anterior ischemic optic neuropathy. J Natl Med Assoc. 1996;88:369-373.
34. Jirásková N, Rozsíval P, Hobza V. Amiodaronová neuropatie optiku z pohledu neurooftalmologa. Cs Oftal. 1996;52:308-318.
35. Swann PG, McLaren K. Ocular complications from amiodarone. Optom Today. 1999;34-35.
36. DeWitt CA, Johnson LN, Schoenleber DB, et al. Visual function in patients with optic nerve pallor (optic atrophy). J Natl Med Assoc. 2003;95: 394-397.
37. Johnson LN, Krohel GB, Madsen RW, et al. The role of weight loss and acetozolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998;105:2313-2317.
38. Boghen DR. Glaser JS. Ischaemic optic neuropathy. The clinical profile and history. Brain. 1975;98:689-708.
39. Johnson LN, Guy ME, Krohel GB, et al. Levodopa may improve vision loss in recent onset nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2000;107:521-526.
40. Hayreh SS. Anterior ischemic optic neuropathy: differentiation of arteritic from nonarteritic type and its management. Eye. 1990;4:25-41.
41. Ischemic Optic Neuropathy Decompression Trial (IONDT) Study Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol. 1996;114:1366-1374.
42. Somani P. Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose, and drug concentrations to intracellular inclusion bodies. J Clin Pharmacol. 1989;29:405-412.
43. Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol. 1997;20:608-618.
44. Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 2000;67:642-652.
45. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J. 1983;106:840-847.
46. Moorthy RS, Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opinion Ophthalmol. 1999;10:438-446.
47. Vrobel TR, Miller PE, Mostow ND, et al. A general overview of amiodarone toxicity: its prevention, detection, and management, Prog Cardiovasc Dis. 1989;31:393-426.
48. Rennie IG. Clinically important ocular reactions to systemic drug therapy. Drug Safety. 1993;9:196-211.
49. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J. 1985;109:975-983.
50. Duff GR, Fraser AG. Impairment of colour vision associated with amiodarone keratopathy. Acta Ophthalmol. 1987;65:48-52.
51. Ikäheimo K, Kettunen R, Mäntyjärvi M. Visual functions and adverse ocular effects in patients with amiodarone medication, Acta Ophthalmol Scand. 2002;80:59-63.
52. Newman NJ, Scherer R, Langenberg P, et al. The fellow eye. in NAION: Report from the Ischemic Optic Neuropathy Decompression Trial Follow-Up Study. Am J Ophthalmol. 2002;134:317-328.
53. Johnson LN, Kuo HC, Arnold AC, HLA-A29 as a potential risk factor for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1993; 115:540-542.
54. Mojon DS, Hegdes III TR, Ehrenberg B, et al. Association between sleep apnea syndrome and nanarteritic anterior ischemic optic neuropathy. Arch Ophthalmol. 2002;120:601-605.
55. Repka MX, Savino PJ, Schatz NJ, et al. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol. 1983; 96:478-483.
56. Beck RW, Savino PJ, Repka MX, et al. Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology. 1984;91:1334-1337.
57. Feit RH, Tomsak RL, Ellenberger C. Structural factors in the pathogenesis of ischemic optic neuropathy. Am J Ophthalmol. 1984;98:105-108, 649-650.
58. Guyer DR, Miller NR, Auer CL, et al. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. Arch Ophthalmol. 1985;103:1136-1142.
59. Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology. 1987;94: 1503-1508.
60. Hayreh SS, Joos KM, Podhajsky PA, et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;118:766-780.
61. Jacobson DM, Vierkant RA, Belongia EA. Nonarteritic anterior ischemic optic neuropathy. A case-control study of potential risk factors. Arch Ophthalmol. 1997;115:1403-1407.
62. Weger M, Haas A, Stanger O, et al. Chlamydia pneumoniae seropositivity and the risk of nonarteritic ischemic optic neuropathy. Ophthalmology. 2002;109:749-752.
63. Burde RM. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1993;116:759-764.
64. Lopez AC, Lopez AM, Jimenez SF, et al. Acute intracranial hypertension during amiodarone infusion. Crit Care Med. 1985;13:688-689.
65. Slavin ML. Chronic asymptomatic ischemic optic neuropathy. A report of two cases in adults with diabetes mellitus. J Clin Neuro-Ophthalmol. 1987;7:198-201.
66. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30:791-798.
67. Shukla R, Jowett NI, Thompson DR, et al. Side effects with amiodarone therapy. Postgrad Med J. 1994;70:492-498.
68. Harris L, McKenna WJ, Rowland E, et al. Side effects of long-term amiodarone therapy. Circulation. 1983;67:45-51.
69. Manolis AS, Tordjman T, Mack KD, et al. Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature. Arch Int Med. 1987;147:1805-1809.
70. Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology. 1984;34:669-671.
71. Pellissier JF, Pouget J, Cros D, et al. Peripheral neuropathy induced by amiodarone chlorhydrate. A clinicopathological study. J Neurol Sci. 1984;63: 251-266.
72. Meier C, Kauer B, Müller U, et al. Neuromyopathy during chronic amiodarone treatment. A case report. J Neurol. 1979;220:231-239.
73. Jacobs JM, Costa-Jussa FR, The pathology of amiodarone neurotocicity. II. Peripheral neuropathy in man. Brain. 1985;108:753-769.
74. Costa-Jussa FR, Jacobs JM. The pathology of amiodarone neurotoxicity. I. Experimental studies with reference to changes in other tissues. Brain. 1985;108:735-752.
75. Gibson JM, Fielder AR, Garner A, et al. Severe ocular side effects of perhexilene maleate: case report. Br J Ophthalmol. 1984;68:553-560.
76. Atkinson AB, McAreavey D, Trope G. Papilledema and hepatic dysfunction apparently induced by perhexilene maleate (Pexid). Br Heart J. 1980;43:490-491.
77. Behrens MM. Optic atrophy in children after diiodohydroxyquin therapy. JAMA. 1974;228:693-694.
78. Bockhardt H, Drenckhald D, Lüllmann-Rauch R. Amiodarone-induced lipidosis-like alterations in ocular tissues of rat. Graefes Arch Klin Exp Ophthalmol. 1978;207:91-96.
79. Kaplan LJ, Cappaert WE. Amiodarone keratopathy. Correlation to dosage and duration. Arch Ophthalmol. 1982;100:601-602.
80. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Int Med. 2003;138:338-346.
81. Germain DP. Fabry disease: recent advances in enzyme replacement therapy. Exp Opinion Invest Drug. 2002;11:1467-1476.
82. D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy, drug-induced lipid storage disease. Arch Ophthalmol. 1981;99:257-261.
83. Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease. Genetics Med. 2003;5:144-53.
84. Mäntyjärvi M, Tuppurainen K, Ikäheimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 1998;42:360-366.
85. Mansour AM, Puklin JE, O'Grady R. Optic nerve ultrastructure following amiodarone therapy. J Clin Neuro-Ophthalmol. 1988;8:231-237.
86. Vereckei A, Blazovics A, Gyorgy I, et al. The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol. 1993;4: 161-177.
87. Paillous N, Fery-Forgues S. Is there a link between the phototoxic or antioxidant properties of amiodarone, an antiarrhythmic drug, and its lipophilic character? Biochem Pnarmacol. 1994;48:851-857.
88. Honegger UE, Scuntaro I, Wiesmann UN. Vitamin E reduces accumulation of amiodarone and desethylamiodarone and inhibits phospholipidosis in cultured human cells. Biochem Pharmacol. 1995;49:1741-1745.
89. François J. Cornea verticillata. Bull Soc Belge Ophtalmol. 1968;150:656-670.
90. Orlando RG, Dangel ME, Schall SF. Clinical experience and grading of amiodarone keratopathy. Ophthalmology. 1984;91:1184-1187.